Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
Search results
505 results
-
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
In development [GID-TAG393] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Thrombophilia [ID393]
In development [GID-TAG374] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Falls - faller's clinics [ID103]
In development [GID-TAG375] Expected publication date: TBC
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Venous thromboembolism (prevention) - rivaroxaban [ID463]
In development [GID-TAG427] Expected publication date: TBC
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
Workplace health for employees with disabilities and long-term conditions
In development [GID-PHG58] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]
In development [GID-TA10224] Expected publication date: TBC
-
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470
In development [GID-TA10354] Expected publication date: TBC
-
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]
In development [GID-TA10625] Expected publication date: TBC
-
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
In development [GID-TA10447] Expected publication date: TBC
-
Eculizumab for treating refractory myasthenia gravis [ID1064]
In development [GID-TA10176] Expected publication date: TBC
-
Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]
In development [GID-TA10628] Expected publication date: TBC
-
Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]
In development [GID-TA10627] Expected publication date: TBC
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
In development [GID-TA10329] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178
In development [GID-TA10199] Expected publication date: TBC
-
Ranibizumab for treating diabetic retinopathy [ID1592]
In development [GID-TA10521] Expected publication date: TBC